Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2004

View Archived Issues

A sustained-release formulation of lanreotide shows efficacy in acromegaly

Good safety and pharmacokinetic profile of intranasal PYY3-36 in healthy volunteers

Oralin reported to improve mealtime glycemic control in type 2 diabetes

Comparison of sleep induction with melatonin, zaleplon, zopiclone and temazepam

Elan submits Prialt NDA amendment

Remoxy results demonstrate Oradur utility

ZymoGenetics licenses to Novo Nordisk rights to IL-28A, IL-29 and IL-31

FDA approval of NeutroSpec for diagnosis of appendicitis

ViraGen licenses Oxford BioMedica's LentiVector gene delivery technology

AltaRex signs distribution agreement with Dompe

sBLA filed for Bexxar

NeoRx files IND for phase II study of STR in metastatic breast cancer

IDEA receives milestone for progression of targeted pain therapeutic

Second clinical trial evaluates trans-NV-04

Pharming and Esteve reach agreement on rhC1INH

NexMed and Schering AG sign Alprox-TD agreement

U.S. phase II study of FM-VP4 planned for next year

Pharmion launches Vidaza

Forest and PAION enter agreement for desmoteplase in U.S. and Canada

Guidant and Miravant to collaborate on cardiovascular PDT development

Dosing commences in phase III trial of TransMID for glioblastoma multiforme

Positive opinion handed down in Europe for Protelos

Wilzin recommended for approval in Europe for Wilson's disease

Novel DPP-IV inhibitors claimed by Boehringer Ingelheim

FKBP12 ligands for neurodegenerative diseases in early development at Taisho

Boehringer Ingelheim patent describes series of cytokine inhibitors

Modulators of tyrosine kinase-mediated signal transduction disclosed in patent

PDE4 inhibitors prepared and tested at elbion

Gastric and intestinal protectants claimed in Altana patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...